Asset Details
Do you wish to reserve the book?
Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)
Do you wish to request the book?
Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)
2025
Overview
Background Effective cancer management include comprehensive evaluation of treatment patterns to ensure optimal resource utilization. This is a single center study review anticancer drug utilization, with an emphasis on adherence to the World Health Organization Essential Medicines List (WHO EML) and regional prescribing trends amid increasing cancer incidence. Methods We conducted a retrospective cohort study of 512 adult patients with histologically confirmed malignant neoplasms that were managed with anti-cancer therapy at King Khaled Hospital, Najran, from 2014 to 2022. Data extraction included demographic characteristics, treatment regimens, and supportive medications, analyzed using IBM SPSS Statistics (version 21). Prescription quality was assessed against WHO EML criteria and Saudi Food and Drug Authority (SFDA) standards. Results The study revealed slight male predominance (56.4%), with a mean age 55.2 ± 17.0 years. Gastrointestinal (29.7%) and breast cancers (25.8%) accounted for the majority of cases, and 46.7% of patients presented with metastatic disease. First-line regimens predominantly included doxorubicin-cyclophosphamide (20.1%) and FOLFOX (13.5%). Notably, 86.7% of prescribed agents were listed on the WHO EML, surpassing the 85.3% benchmark, and 90.1% were generics. Supportive care commonly involved metoclopramide-based antiemetics (76.1%). Medication shortages occurred in 8.4% of cases, predominantly involving BCG. Conclusion Our findings demonstrate an optimal utilization of WHO Essential Medicines List, reflecting evidence-based, cost-effective prescribing practices that exceed international benchmarks. Despite the observed supply chain vulnerabilities, the study reinforces the relevance and applicability of the WHO model at the regional level.
Publisher
F1000 Research Ltd
Subject
